Clinical landscape analysis for Tumor Infiltrating Lymphocytes

Challenge A European investor was refocusing its investment efforts and considering targeting the oncology cell therapy space. It had a particular interest in tumor infiltrating lymphocytes (TILs)...
Learn More

Sales forecast for nanoparticle-drug-conjugate in small cell lung cancer

Challenge: A UK-based pharma company specializing in oncology drug development sought to understand the potential value of a nanoparticle drug product in small cell lung cancer (SCLC). Alacrita was...
Learn More

Valuation of an integrin-targeting oncology asset

Challenge A preclinical-stage company developing an integrin-targeting oncology asset engaged Alacrita to quantify the value potential of its lead asset in pancreatic ductal adenocarcinoma (PDAC),...
Learn More

Clinical protocol review in oncology

Challenge A biopharma company developing microbiome therapeutics asked Alacrita to conduct a detailed protocol review of a clinical study designed for its lead asset in patients with advanced solid...
Learn More

Technical and commercial due diligence of antibody against metastatic cancers

Challenge: A VC firm was exploring investment in a spin-out company with an antibody targeted at metastatic cancer indications. Before committing to the financing round, the investor required...
Learn More

Due diligence for in-licensing opportunities in oncology

Challenge: A lean pharma company reached out to Alacrita for due diligence support regarding three oncology assets of interest, prior to entering into licensing negotiations. The client requested an...
Learn More

Internal DD and investor readiness for pre-clinical biotech company

Challenge: A late pre-clinical biotech company engaged in the development of antibody drug conjugates (ADCs) targeting GPCRs for treatment of solid tumors asked Alacrita to conduct an internal due...
Learn More

Valuation of deal for prophylactic mAbs against SARS-CoV-2

Challenge A recently emerged biotech company developing prophylactic monoclonal antibodies (mAbs) against a major viral target for immunocompromised patients asked Alacrita to develop an independent...
Learn More

Global sales forecast for a small molecule in hepatocellular carcinoma

Challenge A UK-based oncology drug development company was planning to in license a small molecule in development for hepatocellular carcinoma (HCC) and Rhabdomyosarcoma. Alacrita was commissioned to...
Learn More

Oncology clinical expert input and asset valuation

Challenge A clinical stage immuno-oncology biotech company spun out from a leading university had completed a Phase I clinical trial in ovarian cancer patients with its lead antibody. In response to...
Learn More

Defining a clinical strategy in oncology for a platform technology

Challenge: A venture capital-backed platform technology company wanted to develop its internal pipeline of therapeutic oncology candidates, while allowing prospective partners to access the...
Learn More

Market landscape exercise for three oncology therapeutics

Challenge A leading private US academic institution, recognizing the need to further develop early discoveries from the university in order to facilitate industry partnerships and clinical...
Learn More
1 2